Call Start: 16:30 January 1, 0000 5:07 PM ET

MaxCyte, Inc. (NASDAQ:MXCT)

Q2 2022 Earnings Conference Call

August 10, 2022 16:30 ET

Company Participants

Sean Menarguez - Director of Investor Relations

Doug Doerfler - Founder, President & Chief Executive Officer

Ron Holtz - Chief Financial Officer

Conference Call Participants

Max Masucci - Cowen

Julie Simmonds - Panmure

Dan Arias - Stifel

Operator

Good day and thank you for standing by and welcome to MaxCyte Second Quarter 2022 Earnings Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded.

I would now like to hand the conference over to your speaker today, Sean Menarguez, Director of Investor Relations. Please go ahead.

Sean Menarguez

Thank you, Norma and good afternoon, everyone. My name is Sean Menarguez and I'm the Director of Investor Relations here at MaxCyte. Thank you all for participating in today's conference call. On the call from MaxCyte, we have Doug Doerfler, President and Chief Executive Officer; and Ron Holtz, Interim Chief Financial Officer.

Earlier today, MaxCyte released financial results for the second quarter ended June 30, 2022. A copy of the press release is available on the company's website. Before we begin, I need to read the following statements. Statements or comments made during this call may be forward-looking statements within the meaning of federal securities laws. Any statements contained in this call that relate to expectations or predictions of future events, results or performance are forward-looking statements. Actual results may differ materially from those expressed or implied in any forward-looking statements due to a variety of factors, which are discussed in detail in our SEC filings. The company undertakes no obligation to publicly update any forward-looking statements, whether because of new information, future events or otherwise.

And with that, I will turn the call over to Doug.

Doug Doerfler

Well, thank you, Sean and good afternoon, everyone and thank you for joining MaxCyte's second quarter earnings call. I will begin with a discussion of our business and operational highlights during the quarter, followed by a detailed financial review from Ron, along with an update on our revenue outlook for the year. We will then open the call for questions.

I am very pleased with our start to 2022, as our team continues to deliver on the financial and strategic objectives in our plan. MaxCyte's ExPERT platform and team continue to be the premier cell engineering technology and partner, enabling the development of a growing set of advanced cell-based therapeutics. With additional resources at hand, we continue to invest in our people and capabilities at a measured but healthy rate as we seek to take advantage of the growing markets and support our customers' and partners' growth. Ron will provide more details later in the call but I’d note that we generated very strong second quarter 2022 results, as outlined in the press release this morning.